PolyPid (PYPD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PolyPid (PYPD) has a cash flow conversion efficiency ratio of -5.413x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.55 Million) by net assets ($5.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PolyPid - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how PolyPid's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PolyPid (PYPD) financial obligations for a breakdown of total debt and financial obligations.
PolyPid Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PolyPid ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pender Growth Fund VCC Inc
V:PTF
|
-0.023x |
|
Fairchem Organics Limited
NSE:FAIRCHEMOR
|
0.016x |
|
GreenMobility A/S
CO:GREENM
|
0.802x |
|
Inmax Holding Co Ltd
TWO:1591
|
-0.093x |
|
Huvis Corporation
KO:079980
|
-0.024x |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
-0.032x |
|
South West Pinnacle Exploration Limited
NSE:SOUTHWEST
|
-0.017x |
|
SanDi Properties Co Ltd
TW:1438
|
0.129x |
Annual Cash Flow Conversion Efficiency for PolyPid (2012–2024)
The table below shows the annual cash flow conversion efficiency of PolyPid from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of PolyPid.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.68 Million | $-21.96 Million | -2.858x | -134.76% |
| 2023-12-31 | $-2.10 Million | $-17.24 Million | 8.223x | +239.68% |
| 2022-12-31 | $5.83 Million | $-34.32 Million | -5.887x | -553.70% |
| 2021-12-31 | $35.96 Million | $-32.39 Million | -0.901x | -203.50% |
| 2020-12-31 | $72.78 Million | $-21.60 Million | -0.297x | +47.12% |
| 2019-12-31 | $30.93 Million | $-17.36 Million | -0.561x | -374.90% |
| 2018-12-31 | $-81.71 Million | $-16.68 Million | 0.204x | +46.96% |
| 2017-12-31 | $-88.65 Million | $-12.31 Million | 0.139x | -51.54% |
| 2016-12-31 | $-33.96 Million | $-9.73 Million | 0.287x | -98.99% |
| 2015-12-31 | $-231.00K | $-6.57 Million | 28.455x | +9008.17% |
| 2013-12-31 | $-8.06 Million | $-2.52 Million | 0.312x | -23.47% |
| 2012-12-31 | $-4.55 Million | $-1.86 Million | 0.408x | -- |
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients unde… Read more